What one share of Biocryst Pharmaceuticals holds
We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions.
Biocryst Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.02 |
|---|---|
| Profit | −$1.64 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | $1.60 |
| Cash and investments | $0.61 |
| Debt | $1.56 |
| Book value | −$1.78 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.11 | −$1.09 | $0.00 | −$0.81 | — | −$0.11 |
| 2021 | $0.88 | −$1.03 | $0.01 | −$0.81 | — | −$0.58 |
| 2022 | $1.46 | −$1.33 | $0.01 | −$0.88 | — | −$1.57 |
| 2023 | $1.72 | −$1.18 | $0.01 | −$0.51 | — | −$2.21 |
| 2024 | $2.18 | −$0.43 | $0.01 | −$0.26 | — | −$2.28 |
| 2025 | $4.00 | $1.21 | $0.01 | $1.58 | — | −$0.56 |
Common questions about Biocryst Pharmaceuticals
How much does one share of Biocryst Pharmaceuticals earn?
Over the last 12 months, Biocryst Pharmaceuticals lost $1.64 for each share on $4.02 of sales.
Does Biocryst Pharmaceuticals pay a dividend?
Biocryst Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Biocryst Pharmaceuticals’s book value per share?
Biocryst Pharmaceuticals’s book value is negative (−$1.78 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Biocryst Pharmaceuticals have?
Each share of Biocryst Pharmaceuticals has $0.61 of cash and investments and $1.56 of debt, as of June 30, 2026.
What is Biocryst Pharmaceuticals’s free cash flow per share?
$1.60 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Biocryst Pharmaceuticals bought back shares?
Biocryst Pharmaceuticals’s share count rose about 31% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.